WSO December 2023 – Issue 3 - 1207

Suzuki et al.
1207
was approved for the administration of alteplase at 0.6 mg/
kg in Japan, where the present study was performed.29
However, applying the internationally approved higher dosage
of 0.9 mg/kg might impact the clinical outcomes. Thus,
further studies including multicenter data assessed using
automated software are required to validate our results.
Detailed DWI-ASPECTS is a novel method to measure
infarct core volume and clinical outcomes more accurately
than conventional DWI-ASPECTS in patients with anterior
circulation ischemic stroke who underwent EVT, particularly
in those with low conventional DWI-ASPECTS.
Acknowledgements
None.
Data availability statement
The dataset generated during the current study is not publicly
available but are available from the corresponding author on reasonable
request.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: Dr. Kimura received lecture fees from Bristol-Myers
Squibb Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Bayer
Healthcare Co. Ltd., and Daiichi Sankyo Co.; research funding
from Nippon Boehringer Ingelheim Co. Ltd., Daiichi Sankyo Co.,
Pfizer Japan Inc., Medtronic Co. Ltd., and Teijin Pharma Ltd.; and
personal funding from the 38th Mihara Cerebrovascular Disorder
Research Promotion Fund Ltd. Dr. Liebeskind receives support
for acting as an imaging core laboratory for Cerenovus, Genentech,
Medtronic, Stryker, and Rapid Medical. The other authors report
no conflicts.
Funding
The author(s) received no financial support for the research,
authorship, and/or publication of this article.
Research ethics and patient consent
This study was approved by the ethics committee of Nippon
Medical School Hospital (26-10-398) and written informed consent
was obtained from patients or their relatives.
ORCID iDs
Kentaro Suzuki
Takehiro Katano
Kazumi Kimura
References
1. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy
6 to 24 hours after stroke with a mismatch between deficit and
infarct. N Engl J Med 2018; 378: 11-21.
2. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for
stroke at 6 to 16 hours with selection by perfusion imaging. N
Engl J Med 2018; 378: 708-718.
https://orcid.org/0000-0001-7607-2607
https://orcid.org/0000-0002-8176-0938
https://orcid.org/0000-0003-2386-5528
3. Yoshimura S, Sakai N, Yamagami H, et al. Endovascular therapy
for acute stroke with a large ischemic region. N Engl J
Med 2022; 386: 1303-1313.
4. Sarraj A, Hassan AE, Abraham MG, et al. Trial of endovascular
thrombectomy for large ischemic strokes. N Engl J Med
2023; 388: 1259-1271.
5. Huo X, Ma G, Tong X, et al. Trial of endovascular therapy for
acute ischemic stroke with large infarct. N Engl J Med 2023;
388: 1272-1283.
6. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines
for the early management of patients with acute ischemic
stroke: a guideline for healthcare professionals from the
American Heart Association/American Stroke Association.
Stroke 2018; 49: e46-e110.
7. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance
imaging profiles predict clinical response to early reperfusion:
the diffusion and perfusion imaging evaluation for understanding
stroke evolution (DEFUSE) study. Ann Neurol 2006;
60: 508-517.
8. Nezu T, Koga M, Nakagawara J, et al. Early ischemic change
on CT versus diffusion-weighted imaging for patients with
stroke receiving intravenous recombinant tissue-type plasminogen
activator therapy: stroke acute management with urgent
risk-factor assessment and improvement (SAMURAI) rt-PA
registry. Stroke 2011; 42: 2196-2200.
9. Aoki J, Kimura K, Shibazaki K and Sakamoto Y. DWIASPECTS
as a predictor of dramatic recovery after intravenous
recombinant tissue plasminogen activator administration
in patients with middle cerebral artery occlusion. Stroke 2013;
44: 534-537.
10. Suzuki K, Matsumaru Y, Takeuchi M, et al. Effect of mechanical
thrombectomy without vs with intravenous thrombolysis
on functional outcome among patients with acute ischemic
stroke: the skip randomized clinical trial. JAMA 2021; 325:
244-253.
11. Barber PA, Demchuk AM, Zhang J and Buchan AM. Validity
and reliability of a quantitative computed tomography score in
predicting outcome of hyperacute stroke before thrombolytic
therapy. ASPECTS study group. Alberta stroke programme
early CT score. Lancet 2000; 355: 1670-1674.
12. Barber PA, Hill MD, Eliasziw M, et al. Imaging of the brain in
acute ischaemic stroke: comparison of computed tomography
and magnetic resonance diffusion-weighted imaging. J Neurol
Neurosurg Psychiatry 2005; 76: 1528-1533.
13. Desilles JP, Consoli A, Redjem H, et al. Successful reperfusion
with mechanical thrombectomy is associated with
reduced disability and mortality in patients with pretreatment
diffusion-weighted imaging-Alberta stroke program early
computed tomography score ⩽6. Stroke 2017; 48: 963-969.
14. Sarraj A, Grotta JC, Pujara DK, Shaker F and Tsivgoulis G.
Triage imaging and outcome measures for large core stroke
thrombectomy-a systematic review and meta-analysis. J
Neurointerv Surg 2020; 12: 1172-1179.
15. Kerleroux B, Janot K, Hak JF, et al. Mechanical thrombectomy
in patients with a large ischemic volume at presentation:
systematic review and meta-analysis. J Stroke 2021; 23:
358-366.
16. Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D slicer as
an image computing platform for the quantitative imaging
network. Magn Reson Imaging 2012; 30: 1323-1341.
International Journal of Stroke, 18(10)
https://www.orcid.org/0000-0001-7607-2607 https://www.orcid.org/0000-0002-8176-0938 https://www.orcid.org/0000-0003-2386-5528
WSO December 2023 – Issue 3

Table of Contents for the Digital Edition of WSO December 2023 – Issue 3
